Quantase™ Neonatal TGAL Assay

The Bio-Rad Assay

  • Not subject to the interferences commonly observed with fluorescent and bacterial inhibition methods
  • Simplified protocols can be used on most plate readers
  • Rapid results in under 2 hours

Product Highlights

  • Cost effective
  • Easily automated
  • Environmentally friendly, no flammables
  • Rapid procedure

Flexibility for Your Laboratory Needs

Total Galactose

  1. Punch sample
  2. Add 5 µL elution reagent
  3. Incubate at RT for 30 minutes  
  4. Vacuum transfer eluate
  5. Add 100 µL enzyme reagent
  6. Incubate at RT for 30 minutes  
  7. Add 100 µL color reagent
  8. Incubate at RT for 2 minutes
  9. Read 570 nm and 690 nm

Clinical Background

Galactosemia is an inherited disorder of galactose metabolism, caused by a deficiency in one of three enzymes, the most important being galactose-1-phosphate uridyl transferase. Galactosemia may also be caused by a lack of galactokinase or UDP-galactose-4-epimerase activity.

Long-term consequences of galactosemia include mental retardation, developmental abnormalities, and even death. The worldwide prevalence of galactosemia is estimated to be 1:60,000–1:80,000. The Quantase Neonatal Total Galactose Screening Assay is an enzymatic colorimetric end-point method for the determination of total D(+) galactose in dried-blood spot specimens.


Scroll upScroll down

Bio-Rad's Quantase™ Neonatal Total Galactose Assay (TGAL) is an enzymatic, colorimetric end-point method for the determination of total D(+)galactose [D(+)galactose + galactose-1-phosphate] in dried blood spot specimens. Recognized as a worldwide market leader in TGAL screening, this assay is easily automated and can be performed with any microplate reader.

This product contains electrical or electronic material. Learn more about Bio-Rad's EU Recycle Program

Get Help
Sign Up for Bio-Rad Updates!
Enter your email address below to receive your choice of the latest news, promotions, and more.